Anzeige
Mehr »
Samstag, 09.08.2025 - Börsentäglich über 12.000 News
Das Kupferangebot bricht ein - und dieser neue Fund kommt genau zur richtigen Zeit
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A3ESDF | ISIN: US00972G2075 | Ticker-Symbol: CLA
Tradegate
08.08.25 | 14:53
0,870 Euro
+2,35 % +0,020
Branche
Pharma
Aktienmarkt
Sonstige
1-Jahres-Chart
AKARI THERAPEUTICS PLC ADR Chart 1 Jahr
5-Tage-Chart
AKARI THERAPEUTICS PLC ADR 5-Tage-Chart
RealtimeGeldBriefZeit
0,8100,90008.08.
0,8200,87508.08.

Aktuelle News zur AKARI THERAPEUTICS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
29.07.Akari Therapeutics Plc - S-8, Securities to be offered to employees in employee benefit plans2
29.07.Akari Therapeutics Plc: Akari Therapeutics Releases Virtual Investor "What This Means" Segment1
23.07.Akari Therapeutics treibt ADC-Krebstherapie mit PH1-Wirkstofftechnologie voran5
23.07.Akari Therapeutics advances cancer-fighting ADC technology with PH1 payload1
AKARI THERAPEUTICS Aktie jetzt für 0€ handeln
23.07.Akari Therapeutics Plc: Akari Therapeutics Continues Key Research on its Novel Antibody Drug Conjugate Payload PH1 to Further Demonstrate its Unique Ability to Target Cancers Fueled by Oncogenic Drivers109PH1 modulates RNA splicing, causing cancer cell death while activating the immune system to attack cancer throughout the body Company advancing pipeline of ADCs using PH1 payload across both Trop2...
► Artikel lesen
18.07.Akari Therapeutics: Maxim Group startet Coverage mit Kaufempfehlung und sieht Kurspotenzial2
18.07.Maxim Group initiates coverage on Akari Therapeutics stock with Buy rating2
01.07.Akari Therapeutics Plc - 8-K, Current Report2
18.06.Akari Therapeutics secures Indian patent for cancer drug payload2
18.06.Akari Therapeutics Plc: Akari Therapeutics Bolsters Global IP Estate for its Novel Antibody Drug Conjugate (ADC) Immuno-Oncology Payload, PH1, with Recent Granting of Patent Protection Across India475Differentiated PH1 payload is a spliceosome inhibitor designed to inhibit RNA splicing, leading to cancer cell death and activation of immune system through multiple mechanisms India represents a...
► Artikel lesen
29.05.Akari Therapeutics Plc: Akari Therapeutics Releases "Meet the Team" Video Featuring Recently Appointed Mark F. Kubik, Head of Business Development - Oncology3
22.05.Akari Therapeutics Plc: Akari Therapeutics to Present at LIVE! with Webull Corporate Connect: Virtual Biotech Investment Webinar5
15.05.Akari Therapeutics Plc - 8-K, Current Report-
15.05.Akari Therapeutics GAAP EPS of $0.002
15.05.Akari Therapeutics Plc: Akari Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update225Advancing development of novel Antibody Drug Conjugates (ADCs) with immuno-oncology payloads to treat multiple cancer tumors Rounding out executive team with deep oncology experience by appointing...
► Artikel lesen
14.05.Akari Therapeutics Plc - 10-Q, Quarterly Report1
01.05.Akari Therapeutics ernennt neuen Leiter für Onkologie-Geschäftsentwicklung3
01.05.Akari Therapeutics appoints new head of oncology business1
01.05.Akari Therapeutics Plc: Akari Therapeutics Appoints Mark F. Kubik as Head of Business Development - Oncology252Global expertise in establishing and executing transformative transactions which have led to multiple approved therapeutic products Successful track record across oncology therapeutics including ADCs...
► Artikel lesen
16.04.Akari Therapeutics GAAP EPS of $0.002
Weiter >>
38 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1